The startup has developed a platform that allows precise engineering of optical properties to provide high-resolution analysis of single cells by high throughput flow cytometry.
The St. Louis-based firm will use the funds to develop its colorectal cancer screening test, which measures eukaryotic RNA isolated from epithelial cells in stool.
The company plans to use the funding to finish developing and commercially launch its HD-Mapping whole-genome electronic mapping platform.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
The firm will use the funding to advance its enzymatic DNA synthesis technology, which has applications in life sciences, information storage, synthetic biology, and electronics.
The Seattle startup is looking to partner with pharmaceutical companies and offer its yeast fusion sequencing technology as a contracted research service.
The Netherlands-based biotech firm will use the funding to develop a group of biomarkers to detect colorectal cancer.
The firm will offer €4.4 billion of euro-denominated notes and $900 million in dollar-denominated notes. It will redeem another $4.5 billion in outstanding notes.
The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.
By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.